BL-918 is a small molecule activator of ULK1 with EC50 of 24 nM (243% kinase activity at 100 nM), induces autophagy via the ULK complex in SH-SY5Y cells.

BL-AD008 (BL-AD 008) is a novel small molecule, dual-target activator targeting AMPK/ZIPK; demonstrates remarkable anti-proliferative activities toward cervical cancer cells and could induce apoptosis by death-receptor and mitochondrial pathways; also sho

Blasticidin S hydrochloride is a nucleoside antibiotic isolated from Streptomyces griseochromogenes. Blasticidin S is a potent inhibitor of protein synthesis in both prokaryotic and eukaryotic cells.

BLT-1 is an irreversible Scavenger receptor class B member I (SR-BI) inhibitor that blocks SR-BI-mediated selective lipid uptake and bidirectional cholesterol flux with an IC50 of 50 nM; significantly inhibits baicalin-induced cholesterol efflux in THP-1 macrophages.

BLU-667 trans form is the trans form of BLU-667, which is a highly potent, selective, next generation RET inhibitor..

BLU-782 (BLU782) is a novel potent, selective inhibitor of Activin receptor-like kinase (ALK2) mutant R206H with binding IC50 of <10 Nm.

BM-1197 is a potent, specific dual inhibitor of Bcl-2 and Bcl-xL with Ki of <1 nM, shows >1,000-fold selectivity over Mcl-1.

BM-635 is a small molecule anti-mycobacterial compound acting by inhibiting the mycobacterial membrane protein Large 3 (MmpL3).

BM-957 is a highly potent, dual Bcl-2 and Bcl-xL inhibitor with Ki of <1 nM for both, IC50 of 5.4 and 6.0 nM, respectively.

BML-277 (C 3742) is a selective Chk2 (checkpoint kinase 2) inhibitor with an IC50 of 15 nM.

Bm-MPK1-IN-15b is a potent, orally bioavailable inhibitor of B. malayi stress-activated kinase Bm-MPK1 with IC50 of 24 nM.

BMP signaling agonist sb4 is a small molecule BMP signaling agonist with EC50 of 73.6 nM, enhances the efficacy of BMPs and activates endogenous BMP4 target genes.

BMS 695735 is a potent, selective IGF-1R inhibitor with IC50 of 34 nM.

BMS-189453 (BMS189453, BMS453) is a synthetic retinoid that acts as an agonist of RARβ and an antagonist of RARα and RARγ.

BMS-211 is a prodrug of the parent pan-CK2 inhibitor BMS-699..

BMS-212 is a potent and selective stimulator of glucokinase (GK) (EC50 = 35 nM) that is promisingly used as an antidiabetic.

BMS-214662 is a potent and selective farnesyl transferase inhibitor with potent antitumor activity with an IC50 of 1.35 nM.

BMS-303141 is a potent ATP-citrate lyase (ACL) inhibitor with IC50 value of 0.13 uM (human recombinant ACL).

BMS-394136 is a potent, selective IKur/Kv1.5inhibitor, increases atrial action potential duration (APD) and prolongs AERP but not VERP in both rabbits and beagles..

BMS433771 is a potent, orally active RSV fusion inhibitor, exhibits excellent potency against multiple laboratory and clinical isolates of both group A and B viruses with mean EC50 of 20 nM.

BMS-457 is a potent and selective CCR1 antagonist with binding IC50 of 0.8 nM, >1,000-fold selectivity against other CC family receptors.

BMS-564929 is a potent, selective androgen receptor modulator (SARM) that binds to AR with Ki of 2.11 nM.

BMS-582949 is a dual action p38 Kinase Inhibitor.

BMS-595 (BMS595) is a novel potent, selective, ATP-competitive casein kinase 2 (CK2) inhibitor with IC50 of 1.3 nM (CKα).

BMS-599626 (AC-480) is a potent, selective inhibitor of EGFR and HER2 with IC50 of 20 nM and 30 nM.

BMS-626529 is a novel small-molecule attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T-cells.

BMS-641988 is a potent, selective, nonsteroidal androgen receptor antagonist with Ki of 1.7 nM, MDA-MB-453 cell IC50 of 16 nM.

BMS-654457 is a potent, reversible and direct inhibitor of factor XIa (FXa) with Ki of 0.4 nM.

BMS-699 (BMS699) is a novel potent, selective, ATP-competitive casein kinase 2 (CK2) inhibitor with IC50 of 0.1 nM (CKα).

BMS-741672 is a potent, selective CCR2 antagonist for the treatment of neuropathic pain..

BMS-751324 is a novel clinical prodrug of BMS-582949, which is a highly selective p38α MAPK inhibitor with IC50 of 13 nM.

BMS-795311 is a potent and orally available CETP inhibitor with IC50 of 3.8 nM, inhibits cholesteryl ester (CE) transfer with IC50 of 0.22 uM.

BMS-806 (BMS 378806) is a small molecule gp120/CD4 inhibitor with an IC50 of median 5 nM.

BMS-813160 is a dual CCR2/CCR5 chemokine antagonist.

BMS-817378 is a prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833.

BMS-817399 is a potent, selective, orally bioavailable CCR1 antagonist with binding IC50 of 1 nM, inhibits MIP-1α-induced chemotaxis with IC50 of 6 nM.

BMS-818251 (BMS818251) is a novel potent, small-molecule inhibitor of HIV-1 entry with EC50 of 0.019 nM against e laboratory-adapted HIV-1 strain NL4-3.

BMS-823778 (BMS823778) is an orally available, potent and selective inhibitor of 11βHSD-1 with IC50 of 2.3 nM, displays >10,000-fold selectivity over 11βHSD-2.

BMS-823778 (BMS823778) is an orally available, potent and selective inhibitor of 11βHSD-1 with IC50 of 2.3 nM, displays >10,000-fold selectivity over 11βHSD-2.

BMS-863233, also known as XL-413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity.

BMS-869780 is a potent γ-secretase modulator (GSM) that decreases Aβ1-42 (IC50=5.1 nM) and Aβ1-40 (IC50=25.1 nM) and increases Aβ1-37 and Aβ1-38 without inhibiting overall levels of Aβ peptides or other APP processing intermediates.

BMS-871 is a potent, orally active pan-Notch inhibitor with IC50 of 4/1/4/3 nM for Notch1/2/3/4, respectively.

BMS-884775 is a potent, selective P2Y1 antagonist with IC50 of 0.12 nM.

BMS-919373 is a potent I(Kur)/Kv1.5 channel blocker with IC50 of 50 nM, with selectivity versus hERG, Na, Ca channels and reduced the level of brain penetration.

BMS-932481 (BMS932481) is a potent, selective, orraly active γ-secretase modulator (GSM), shows selectivity for Aβ40 and Aβ42 reduction (IC50=6.6 nM) while sparing total Aβ levels both in vitro and in vivo.

BMS-933043 is a novel highly selective, potent α7 nAChR partial agonist with binding Ki of 3.3 and 8.1 nM for rat and human α7, respectively.

BMS-952048 is a positive allosteric modulator of mGluR5 with EC50 of 10 nM..

BMS-955176 (GSK-3532795) is a second-generation HIV-1 maturation inhibitor that exhibits potent activity (EC50=3.9±3.4 nM) against a library (n=87) of gag/pr recombinant viruses.

BMS-961955 is an potent, allosteric inhibitor of HCV NS5B polymerase with EC50 of 7.9/4.3 nM for GT 1b/1a replicon respectively.

BMS-962212 is a potent, highly selective and reversible small molecule coagulation Factor XIa (FXIa) inhibitor with Ki of 0.7 nM.

BMS-983970 (BMS983970) is a potent, orally active, pan-Notch inhibitor, demonstrates robust anti-tumor activity at tolerated doses in multiple tumor xenograft models..

BMS-984923 (BMS-984923) is a potent silent allosteric modulator (SAM) of mGluR5 with competitive antagonism of MPEPy binding with Ki of 0.6 nM, but has no detectable agonist and antagonist activity at mGluR5 signaling.

BMS-986115 is an orally bioavailable, γ-secretase and pan-Notch inhibitor with potential antineoplastic activity.

BMS-986118 is a potent and selective GPR40 agonist with EC50 of 70 and 63 nM for hGPR40 and mGPR40, shows no PPARγ activity (EC50>47 uM).

BMS-986122 is a potent positive allosteric modulator of μ-opioid receptor, significantly increases the inhibition of forskolin-stimulated adenylyl cyclase activity produced by an EC10 (30 pM) concentration of endomorphin-I in CHO-μ cells..

BMS-986163 is a water-soluble phosphate prodrug of BMS-986169, which is a novel GluN2B negative allosteric modulator (Ki=4.0 nM)..

BMS-986165 is a selective, potent, allosteric inhibitor of tyrosine kinase 2 (Tyk2).

BMS-986166 (BMS986166) is a potent, selective S1P receptor modulator for the treatment of ulcerative colitis..

BMS-986169 is a novel GluN2B negative allosteric modulator, demonstrates high binding affinity for the GluN2B allosteric site (Ki=4.0 nM) and selective inhibition of GluN2B receptor function (IC50=24 nM) in cells.

BMS-986187 is a novel potent, positive allosteric modulator of δ-opioid receptor with EC50 of 30 nM, 100-fold selectivity over μ-opioid receptor..

BMT-046091 (BMT046091) is a potent and selective AAK1 inhibitor with IC50 of 2.8 nM.

BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.

BNC-1 is a small molecule modulator of Amyloid pathology by promoting phosphorylation and activation of Elk-1, a transcriptional repressor of presenilin-1 but not presenilin-2.

BNC105 is a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy.

BNM-III-170 is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.

BNM-III-170 TFA salt is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.

BNS-22 is a small-molecule inhibitor of DNA topoisomerase II, inhibits kinetoplast DNA decatenation that is mediated by human TOP2α and TOP2β in vitro with IC50 of 2.8 and 0.42 uM, respectively.

Bobcat339 (Bobcat 339) is a novel cytosine-based TET enzyme inhibitor with IC50 of 33 uM (TET1) and 73 uM (TET2), but not DNMT3a, does not inhibit the DNA methyltransferase DNMT3a.

BOC-D-FMK is a cell-permeable, irreversible, broad spectrum caspase inhibitor, inhibits apoptosis stimulated by TNF-α with IC50 of 39 uM.

Boc-MLF (TFA) is a peptide, used as a specific formyl peptide receptor (FPR) antagonist, also inhibits the signaling through formyl peptide receptor like 1 (FPRL1) at higher concentrations.

Bohemine is a synthetic, cell-permeable, cyclin-dependent kinase inhibitor.

Borussertib is a potent, first-in-class, covalent-allosteric AKT inhibitor.

BOS172722 (BOS-172722) is a potent, selective MPS1 kinase inhibitor with biochemical IC50 of 11 nM, 100-fold selectivity over CDK2.

Bosutinib is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity.

Box5 is a Wnt5a-derived N-butyloxycarbonyl hexapeptide (t-Boc-Met-Asp-Gly-Cys-Glu-Leu), acts as an Wnt5a antagonist.

BPIPP is an inhibitor of GC-C (guanylyl cyclase type C) that inhibits stimulation of guanylyl cyclase and adenylyl cyclase, suppresses cGMP accumulation in a variety of cell lines (IC50=3.4-11.2 uM).

BPN14770 (BPN-14770) is an allosteric inhibitor of phosphodiesterase 4D (PDE4D) with IC50 of 7.8 and 7.4 nM for human PDE4D7 and PDE4D3 respectively, displays 16-fold less potent against monomeric form of PDE4D lacking the UCR1 dimerization domain (PDE4D2

BPN-15606 (BPN15606) is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 by SHSY5Y neuroblastoma cells with IC50 of 7 nM.

BPR1J-097 is a novel small molecule FLT-3 inhibitor(IC50=11±7 nM) with promising in vivo anti-tumour activities; inhibits FLT-3 D835Y with an IC50 of 3 nM.

BPR1J373 is a potent, orally available multitargeted kinase inhibitor, potently inhibits FLT3, c-KIT, VEGFR1-3, Aurora A, PDGFRα, PDGFRβ, RET, and SRC with IC50 values of <100 nM.

BPR1K653 is a novel potent Aurora kinase inhibitor that inhibits Aurora-A and Aurora-B with IC50 of 24 nM and 45 nM, respectively.

BPTES is a selective inhibitor of Glutaminase GLS1 (KGA)

BQ-788 sodium salt is a potent, selective ETB receptor antagonist (IC50 = 1.2 nM for inhibition of ET-1 binding to human Girardi heart cells); poorly inhibited the binding to ET A receptors in human neuroblastoma cell line SK-N-MC cells (IC(50), 1300 nM).

BQCA is a potent muscarinic M1 receptor positive allosteric modulator with selectivity for M1 over M2-M5.

BQU-082 is a novel potent small GTPase Ral (Ras-like) inhibitor with IC50 of 1.7 uM, displays a dose dependent effect on RalA and RalB activity in H2122 spheroids using the common RalBP1 pull-down assay..

BQU57 is a potent and selective GTPase Ral Inhibitor.

BR101549 (BR-101549) is a novel PPARγ non-TZD agonist with EC50 of 1.73 uM (Amax 120%)..

BR103 is a potent, metabolically stable and highly selective small molecule agonist of complement C3a receptor (C3aR) with EC50 of 22 ± 8  nM.

BR111 is a potent, highly selective and orally active antagonist of complement C3a receptor (C3aR) with IC50 of 85 ± 40  nM (inhibition of hC3a induced Ca2+ release on human macrophages).

BR351 is a brain penetrant MMP inhibitor with IC50s of 4, 2, 11, 50 nM for MMP2, MMP8, MMP9 and MMP13, respectively. Potential tools for the molecular imaging of activated MMPs with PET.

BR351 precursor is a precursor of BR351. BR351 is a brain penetrant MMP inhibitor with IC50s of 4, 2, 11, 50 nM for MMP2, MMP8, MMP9 and MMP13, respectively. Potential tools for the molecular imaging of activated MMPs with PET.

BRACO-19 is a potent small molecule Telomerase inhibitor (IC50=115 nM) that inhibits expression of human telomerase reverse transcriptase (hTERT).

BRACO19 is a telomerase inhibitor that stabilizes G-quadruplexes, targeting telomeric G-quadruplexes, inducing DNA damage and cell-cycle arrest.

Bractoppin is a potent, small-molecule chemical inhibitor that specific selectively blocks phosphopeptide recognition by the BRCA1 tBRCT domain with binding IC50 of 74 nM; shows no inhibition for recognition of cognate biotinylated phosphopeptides to the TOPBP1 tBRCT 7/8, or GRB2 SH2 proteins; engages BRCA1 tBRCT residues recognizing pSer in the consensus motif, pSer-Pro-Thr-Phe, plus an abutting hydrophobic pocket; inhibits substrate recognition detected by Förster resonance energy transfer, and diminishes BRCA1 recruitment to DNA breaks, in turn suppressing damage-induced G2 arrest and assembly of the recombinase, RAD51; selectively interrupts BRCA1 tBRCT-dependent signals evoked by DNA damage.

Bradanicline (TC-5619) is an experimental pharmaceutical drugthat acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors.

Bragsin1 (Bragsin 1) is a specific inhibitor of the ArfGEF BRAG2, affects the trans-Golgi network in a BRAG2- and Arf-dependent manner in cells (IC50=3 uM).

Bragsin2 is a novel PH-domain-binding inhibitor,inhibiting BRAG2-mediated Arf GTPase activation.

Brassinin is a Inducer of phase II enzymes. Moderate and competitive indoleamine 2,3-dioxygenase inhibitor (Ki = 98 μM). Shows chemopreventive effects in vivo. Orally active.

Brassinolide is a predominant plant growth modulator that regulate plant cell elongation. It is active against herpes and arena viruses.

BRD 0476 (ML187) is a selective, moderate inhibitor of ubiquitin-specific peptidase 9X (USP9X), inhibits pancreatic β-cell apoptosis that inhibits IFN-γ-induced JAK2 and STAT1 signaling to promote β-cell survival.

BRD 7389 is an inhibitor of ribosomal S6 kinases (RSK) with IC50 of 1.5 uM, 2.4 uM, and 1.2 uM for RSK1, RSK2, and RSK3, respectively.

BRD 8184 is a potent, selective HDAC6 inhibitor with IC50 of 8 nM, weakly inhibits HDAC2 and HDAC8 (IC50=0.34 and 1.33 uM),has no activity for HDAC4 (IC50>30 uM)..

BRD 8430 is a potent, selective class I HDAC inhibitor (HDAC1>2 >3) with IC50 of 69 nM/560/1300 nM for HDAC1/2/3, respectively.

BRD 8899 is a potent and selective inhibitor of the serine/threonine kinase STK33 with IC50 of 0.11 nM (25 uM ATP).

BRD 9876 is an ATP- and ADP-competitive Eg5 (kinesin-5) inhibitor with Ki of 4 nM, selectively inhibits microtubule-bound Eg5 and inhibits multiple myeloma cell growth (IC50=2.2 uM).

BRD0209 is a highly selective, potent, reversible, ATP-competitive GSK3 inhibitor with IC50 of 19 nM/5 nM for GSK3α/GSK3β respectively.

BRD0705 is a potent, paralog-selective GSK3α inhibitor with IC50 of 66 nM, 8-fold selectivity over GSK3β (IC50=515 nM).

BRD10330 (BRD-10330) is a small molecule that upregulates IL-10 production in BMDCs.

BRD1172 is a highly selective, potent, reversible, ATP-competitive GSK3 inhibitor with IC50 of 3 nM/10 nM for GSK3α/GSK3β, respectively..

BRD1240 is a small-molecule probe that can suppress V-ATPase function, inhibits lysosomal acidification and blocks the maturation of autophagosomes to autolysosomes.

BRD1652 is a highly selective, potent, reversible, ATP-competitive GSK3 inhibitor with IC50 of 0.4 nM/4 nM for GSK3α/GSK3β respectively.

BRD2492 is a highly potent, selective HDAC1/2 inhibitor (IC50=2/19 nM, respectively) that displays excellent selectivity versus HDAC3 (IC50=2.08 uM, ≥110-fold selectivity) and all other HDAC isoforms, increases caspase-3 activation..

BRD2879 (BRD-2879) is a potent, selective inhibitor of IDH1-R132H mutant with IC50 of 50 nM, inhibits cell-based production of R-2HG with EC50 of 0.3 uM.

BRD3308 is a potent, selective HDAC3 inhibitor with IC50 of 54 nM, displays >20-fold selectivity over HDAC1 and HDAC2, >500-fold selectivity over other HDAC isoforms.

BRD3731 is a potent, selective GSK3β inhibitor with IC50 of 15 nM, 14-fold selectivity for GSK3β over GSK3α (IC50=215 nM).

BRD4 inhibitor Compound V is a domain-selective inhibitor of BRD4 with IC50 of 1.8 uM for BRD4 BD1, displays 6- and 16-fold selectivity for BRD4 over BRD2 and BRD3, respectively.

BRD50837 is a potent, selective, small-molecule inhibitor of the Sonic Hedgehog (Shh) pathway with EC50 of 90 nM, partially lowers Gli1 expression at concentrations of 2 uM, a useful probe of Shh signaling pathway. .

BRD5459 is a nontoxic enhancer of reactive oxygen species (ROS) that strongly elevates markers of oxidative stress without causing cell death, ROS inducer..

BRD5529 is a small-molecule inhibitor that disrupts the interaction of CARD9-E3 ubiquitin ligase TRIM62 with IC50 of 8.6 uM.

BRD56491 is a nontoxic enhancer of reactive oxygen species (ROS) that strongly elevates markers of oxidative stress without causing cell death, ROS inducer..

BRD5814 is a potent, selective, highly brain penetrant β-arrestin biased dopamine D2 receptor (D2R) antagonist with Ki of 0.27 uM.

BRD6851 is a potent, cell-active Hedgehog (Hh) pathway inhibitor with IC50 of 0.4 uM against C3H10T1/2 cells undergoing Hh-induced activation acts predominantly as Smo antagonist.

BRD7552 is an inducer of transcription factor PDX1, which increases insulin expression.

BRD9092 is a nontoxic enhancer of reactive oxygen species (ROS) that strongly elevates markers of oxidative stress without causing cell death, ROS inducer..

BRD9526 is a potent, small-molecule inhibitor of the Sonic Hedgehog (Shh) pathway with EC50 of 60 nM, partially lowers Gli1 expression at concentrations of 10 uM, a useful probe of Shh signaling pathway. .

BRD9757 is a potent, selective HDAC6 inhibitor with IC50 of 8 nM, displays >20-fold selectivity over HDAC1/3 and other HDAC isoforms..

BRD9-IN-28 is a highly potent and selective BRD7/9 bromodomain inhibitor with pIC50 of 6.9, Kd of 68 nM for BRD9.

BRD-IN-17 is a cell permeable, family VIII bromodomain tool compound with additional PB1(2) activity over and above that of PFI-3.

BRD-IN-26 is a potent bromodomain inhibitor that binds the fifth bromodomain of PB1 with a KD of 124 nM, SMARCA2B and SMARCA4 with KD values of 262 and 417 nM, respectively.

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells.

Brequinar sodium (DuP-785, Brequinar, NSC 368390) is a potent and selective inhibitor of DHODH with IC50 of 20 nM, triggers differentiation in the ER-HoxA9, U937, and THP1 cells with an ED50 of 1 uM.

Briciclib is a small molecule that suppresses cyclin D1 accumulation in cancer cells.

Brigatinib (AP-26113, AP26113) is a potent, selective, second generation ALK inhibitor with IC50 of 0.62 nM, exhibits about fivefold greater potency in vitro compared with crizotinib.

Brinzolamide is a potent carbonic anhydrase II inhibitor with IC50 of 3.19 nM.

Brivaracetam(UCB-34714) is a 4-substituted pyrrolidone butanamide as agent with significant antiepileptic activity; high affinity SV2A ligand and also shows an ability to inhibit Na+ channels.

Brivudine is a thymidine analogue with antiviral activity, indicated for the early treatment of acute herpes zoster.

BRK inhibitor P21d is a potent, selective, cell permeable inhibitor of breast tumor kinase (Brk, PTK6) with IC50 of 30 nM, shows no inhibitory activity against Aurora B and Lck (IC50>20 uM).

BRL 37344 is a potent and selective β3 adrenoceptor agonist with Ki of 287 nM.

BRL 52537 is a selective κ/μ opioid receptor agonist.

BRL-50481 is a novel and selective inhibitor of phosphodiesterase (PDE) 7 with a Ki value, derived from secondary (Dixon) plots, of 180±10 nM, being at least 200-fold selective for hrPDE7A1 over all other PDEs.

Bromhexine Hydrochloride is a medication prescribed for coughs which works by dissolving hard phlegm.

Bromocriptine (2-Bromoergocriptine.

Bromocriptine (CB-154) is a dopamine D2 receptor agonist (Ki=3 nM) and and various serotonin receptors, also inhibits the release of glutamate by reversing the glutamate GLT1 transporter.

Bromodeoxyuridine (BrdU) is a nucleoside analog that competes with thymidine for incorporation into DNA, and used in the detection of proliferating cells.

Bromosporine is a broad spectrum bromodomain inhibitor. Accelerates FRAP recovery of BRD4 and CREBBP in cells at a concentration of 1 μM.

Bromotriazine (BTZ) is a covalent probe against bromodomain containing proteins with selectively targeting non-catalytic, highly conserved amino acid residues..

BRPF1B TRIM24-IN-34 is a selective BRPF1B/TRIM24 dual inhibitor that binds with KD of 137 and 222 nM, respectively.

BT-11 is an orally active and selective LANCL2 modulator.

BTB-1 is a small molecule inhibitor of the mitotic motor protein Kif18A.

BTK inhibitor 1 (Compound 27)

Btk inhibitor 2 is a Bruton's tyrosine kinase (BTK) inhibitor extracted from patent US 20170224688 A1.

BTK inhibitor 4b is a potent, highly selective inhibitors of BTK with IC50 of 4.2 and 0.9 nM against activated and unactivated BTK, respectively.

BTK-030 is a novel BTK inhibitor.

BTK-IN-23 is a highly potent and selective Btk inhibitor with IC50 of 3 nM.

BTRX-335140 (CYM-53093, BTRX335140, CYM53093) is a potent, selective, orally active κ opioid receptor (KOR) antagonist with IC50 of 0.8 nM.

BTT-266 (BTT266) is a voltage-gated CaV2.2 calcium channel inhibitor that disrupts the CaVα·CaVβ3 protein-protein interaction, directly binds to CaVβ3 with Kd of 3.6 uM.

BTT-369 (BTT369) is a voltage-gated CaV2.2 calcium channel inhibitor that disrupts the CaVα·CaVβ3 protein-protein interaction with Ki of 2.0 uM in FP assays.

BTYNB is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA with IC50 of 5 uM.

BTZO-1 is a cardioprotective agent and Macrophage migration inhibitory factor (MIF) activator, binds to MIF with Kd of 68.6 nM, regulates ARE-mediated gene expression.

BTZO-15 is an active BTZO-1 derivative for ARE-activation with a favorable ADME-Tox profile, induces expression of heme oxygenase-1 (HO-1) and inhibits NO-induced cell death in IEC-18 cells.

BTZO-2 is an active BTZO-1 derivative, an antioxidant response element-activator, provides protection against lethal endotoxic shock in mice..

Budesonide

Bufalin inhibits steroid receptor coactivator 1 (SRC-1) and SRC-3 at doses as low as 5 nM, promotes the degradation of SRC-3 protein, and inhibits cancer cell growth both in vitro and in vivo.

Buflomedil HCl

Bupivacaine HCL

Burimamide oxalate is a potent dual H3/H2 receptor antagonist with Ki of 0.07 and 7.8 uM, respectively.

Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent antagonist of CXCR4 and a well water soluble anti-angiogenic drug that is of potential value in treating choroid neovascularization. Burixafor hydrobromide (TG-0054 hydrobr

Busulfan is a bifunctional alkylating agent.

Butenafine

BVT-948 (SPS8I-3) is a noncompetitive, cell-permeable inhibitor of protein tyrosine phosphatases (PTPs) with IC50 of 0.09-1.7 uM. Results show that the effect of BVT948 (BVT.948) is to strengthen the insulin signal and has no effects on the duration of th

BX-320 is a potent, selective and ATP-competitive inhibitor of PDK1 with IC50 of 30 nM, >20-fold selectivity over PKA.

BX-513 hydrochloride inhibits MIP-1α-induced intracellular calcium mobilization (IC50 = 2.5 μM).

BX517 is a novel phosphoinositide-dependent kinase-1 (PDK1) inhibitor.

BX-667 is a potent P2Y12 receptor antagonist that blocks ADP-induced platelet aggregation in human, dog and rat blood (IC50=97, 317 and 3000 nM respectively).

BYL719 is a potent and selective PI3Kα inhibitor with IC50 of 5 nM, ;liitle or no effect on PI3Kβ/γ/δ.

BZ-194 is a small molecule inhibitor of NAADP action that inhibit NAADP-mediated Ca2+ signaling in T cells, neither interferes with Ca2+ mobilization by IP3 or cyclic ADP-ribose nor with capacitative Ca2+ entry.

BzDANP is a small molecule modulator of pre-miR-29a maturation by Dicer, effectively stabilizes the C-bulged RNA and suppresses Dicer-mediated processing of pre-miR-29a in a concentration dependent manner..

Bz-IEGR-pNA is a colorimetric substrate for Factor Xa.

Bz-Nle-Lys-Arg-Arg-AMC is a substrate for dengue virus NS2B-NS3 and yellow fever virus NS3 protease.

C-021 dihydrochloride is a potent and orally bioavailable CCR4 antagonist with IC50 of 0.14 uM and 0.039 uM for inhibition of chemotaxis in human and mouse, respectively..

C-021 is a potent and orally bioavailable CCR4 antagonist with IC50 of 0.14 uM and 0.039 uM for inhibition of chemotaxis in human and mouse, respectively..

C-215 is a novel inhibitor of mycobacterial membrane protein large 3 (MmpL3) with MIC90 of 16 uM against M. tuberculosis..

C450-0730 is a potent LuxN antagonist that antagonizes LuxN-AI-1 binding with IC50 of 2.7 uM.

C5-benzyl SAHA is a C5-modified SAHA analog that displays dual selectivity to HDAC6 (IC50=0.27 uM) and HDAC8 (IC50=0.38 uM) over HDAC 1, 2, and 3 (IC50=2.9-5.8 uM).

CA-5f is a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer.

Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.

Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.

CaCC(inh)-A01 is a non-selective inhibitor of calcium-activated chloride channels (CaCCs) that blocks ATP-stimulated chloride conductance in human salivary gland, intestinal, and bronchial epithelium (mean IC50 = 10 µM).

CAD-031 (CAD31) is a novel brain penetrant, J147-derivative that has enhanced neurogenic activity over J147 in human neural precursor cells (NPCs).

Cadazolid (ACT-179811) is a novel fluoroquinolone-oxazolidinone antibiotic and a protein synthesis inhibitor.

Calcitonin, Salmon is a calcium regulating hormone secreted from mammalian thyroid parafollicular cells and in non-mammalian species from the ultimobranchial gland.

Calcium levofolinate (Calcium Folinate)

Calcium polystyrene sulfonate is an ion-exchange resin used for reducing blood levels of potassium. Calcium polystyrene sulfonate is used to treat hyperkalemia in patients with chronic kidney disease (CKD).

Calhex-231 is a potent negative allosteric modulator of CaSR that blocks calcium-mediated activation with IC50 of 0.39 uM.

Calindol hydrochloride is a calcimimetic acting agent and positive allosteric modulator (agonist) of CaSR with EC50 of 0.31 uM (stimulated 3H IP accumulation in CHO cells at 2 mM Ca2+).

Calmidazolium chloride (R 24571) is a calmodulin (CaMK) antagonist, antagonizing CaM-dependent phosphodiesterase and calmodulin-induced activation of erythrocyte Ca2+-transporting ATPase with IC50s of 0.15 and 0.35 μM, respectively. Also in anti-cancer re

Calmodulin antagonist. Inhibits Ca2+-calmodulin-dependent phosphodiesterase (IC50 = 28 μM) and myosin light chain kinase (IC50 = 51 μM).

calpeptin is Ca2+-dependent protease,calpain inhibitor

CAM4066 (CAM-4066) is a potent and selective CK2α inhibitor with Kd of 0.32 uM and IC50 of 0.37 uM, shows significantly improved selectivity compared to other CK2α inhibitors. .

CAM4712 (CAM-4712) is a potent and selective CK2α inhibitor with IC50 of 7 uM, exhibits cell growth inhibition in HCT116 cell line with IC50 of 10 uM.